Table 3.
Granulocyte, monocyte, and lymphocyte counts during the follow-up of severe COVID-19 patients.
| Cell populations | Patient status | ICU admission | Week 1 | Week 2 | Week 3 |
|---|---|---|---|---|---|
| Granulocytes | Discharge | 9,000 (8,540–10,200) | 11,135 (10,310–15,510) | 9,800 (8,320–11,550) | 9,150 (5,930–17,580) |
| Death | 9,600 (8,400–10,990) | 13,770 (11,410–16,630) | 11,240 (9,040–13,920) | 10,980 (5,620–19,310) | |
| Monocytes | Discharge | 360 (270–460) | 930 (660–1,180) | 860 (630–940) | 600 (410–1,130) |
| Death | 410 (340–1,180) | 520 (350–720) | 490 (320–750) | 520 (330–750) | |
| Total lymphocytes | Discharge | 830 (610–940) | 1,520 (1,040–1,980) | 1,440 (1,020–1,830) | 1315 (890–1,610) |
| Death | 690 (520–820) | 640 (470–820) | 785 (660–1050) | 940 (600–1,520) | |
| T cells | Discharge | 414 (336–593) | 988 (616–1,314) | 1,094 (708–1,269) | 947 (632–1,187) |
| Death | 361 (263–458) | 400 (320–504) | 537 (471–755) | 705 (366–1,533) | |
| CD4 T cells | Discharge | 226 (168–380) | 734 (370–932) | 663 (521–966) | 723 (444–874) |
| Death | 219 (163–249) | 299 (222–349) | 388 (290–515) | 429 (218–610) | |
| CD8 T cells | Discharge | 128 (102–155) | 258 (162–342) | 177 (139–379) | 202 (155–564) |
| Death | 100 (78–154) | 94 (52–138) | 128 (88–178) | 172 (54–289) | |
| B cells | Discharge | 168 (122–226) | 308 (222–439) | 264 (145–384) | 218 (145–438) |
| Death | 144 (107–173) | 143 (113–198) | 172 (134–230) | 192 (85–255) | |
| NK cells | Discharge | 112 (70–130) | 95 (68–129) | 104 (69–145) | 119 (70–187) |
| Death | 96 (58–137) | 54 (40–75) | 66 (37–127) | 65 (58–150) |
Cell counts (in cells per microliter) are presented as the median and 95% confidence intervals.
NK cells, natural killer cells.